Tetrahydrofurofuran-type lignans inhibit breast cancer-mediated bone destruction by blocking the vicious cycle between cancer cells, osteoblasts and osteoclasts Ah Young JunHyun-Jeong KimWon-Yoon Chung PRECLINICAL STUDIES 15 May 2013 Pages: 1 - 13
Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes Julie C. FriedlandDonald L. SmithDavid A. Proia PRECLINICAL STUDIES Open access 18 May 2013 Pages: 14 - 24
Ring-substituted analogs of 3,3′-diindolylmethane (DIM) induce apoptosis and necrosis in androgen-dependent and –independent prostate cancer cells A. A. GoldbergV. I. TitorenkoJ. T. Sanderson PRECLINICAL STUDIES 25 May 2013 Pages: 25 - 36
Rhodamine-marked bombesin: a novel means for prostate cancer fluorescence imaging Alexander SturzuSumbla SheikhStefan Heckl PRECLINICAL STUDIES 01 June 2013 Pages: 37 - 46
Preclinical analysis of resistance and cross-resistance to low-dose metronomic chemotherapy Annabelle ChowAmy WongUrban Emmenegger PRECLINICAL STUDIES 02 June 2013 Pages: 47 - 59
Antitumor activity of semisynthetic derivatives of Aconitum alkaloids Ainura ChodoevaJean-Jacques BoscJacques Robert PRECLINICAL STUDIES 13 June 2013 Pages: 60 - 67
Structure-activity relationship (SAR) of withanolides to inhibit Hsp90 for its activity in pancreatic cancer cells Mancang GuYanke YuDuxin Sun PRECLINICAL STUDIES 26 July 2013 Pages: 68 - 74
Preclinical studies of targeted therapies for CD20-positive B lymphoid malignancies by Ofatumumab conjugated with auristatin Zhao Hui LiQian ZhangShu Qing Chen PRECLINICAL STUDIES 01 August 2013 Pages: 75 - 86
A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, in patients with advanced solid tumors Shubham PantHoward A. Burris IIIJeffrey R. Infante PHASE I STUDIES Open access 24 March 2013 Pages: 87 - 93
A phase I schedule dependency study of the aurora kinase inhibitor MSC1992371A in combination with gemcitabine in patients with solid tumors E. RaymondJ. AlexandreA. Awada PHASE I STUDIES 29 March 2013 Pages: 94 - 103
Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics Yu SunakawaJunji FuruseYasutsuna Sasaki PHASE I STUDIES Open access 04 April 2013 Pages: 104 - 112
Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: Results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients Douglas A. RubinsonHoward S. HochsterKimmie Ng PHASE I STUDIES 09 April 2013 Pages: 113 - 122
Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non–small cell lung cancer Wilfried E. E. EberhardtPaul MitchellVassiliki Papadimitrakopoulou PHASE I STUDIES 12 April 2013 Pages: 123 - 134
Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors Sunil SharmaElisabeth G. de VriesHoward A. Burris III PHASE I STUDIES 16 April 2013 Pages: 135 - 144
Phase I, dose-finding study of AZD8931, an inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling, in patients with advanced solid tumors S. TjulandinV. MoiseyenkoU. Keilholz PHASE I STUDIES 16 April 2013 Pages: 145 - 153
Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid tumors Aung NaingSiqing FuRazelle Kurzrock PHASE I STUDIES Open access 23 April 2013 Pages: 154 - 159
Phase 1 dose-escalation, pharmacokinetic, and cerebrospinal fluid distribution study of TAK-285, an investigational inhibitor of EGFR and HER2 Patricia LoRussoKarthik VenkatakrishnanEdward A. Sausville PHASE I STUDIES Open access 02 July 2013 Pages: 160 - 170
A Phase II multicenter, open-label, clinical and pharmokinetic trial of PM00104 in patients with advanced Ewing Family of Tumors Robin L. JonesStefano FerrariSant P. Chawla PHASE II STUDIES 01 November 2013 Pages: 171 - 177
A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma Jonathan E. RosenbergRichard M. BamburyDamian A. Laber PHASE II STUDIES 16 November 2013 Pages: 178 - 187
Phase II trial of combination nab-paclitaxel, carboplatin and gemcitabine in first line therapy of advanced urothelial carcinoma Ajjai AlvaStephanie DaignaultMaha Hussain PHASE II STUDIES 10 December 2013 Pages: 188 - 194
Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study Tien HoangToby C. CampbellAnne M. Traynor SHORT REPORT 01 June 2013 Pages: 195 - 199
2-aminothiophene-3-carboxylic acid ester derivatives as novel highly selective cytostatic agents J. BalzariniJ. ThomasR. Romagnoli SHORT REPORT 04 June 2013 Pages: 200 - 210